These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Decision analysis: a primer and application to pain-related studies. Kim J; Nelson R; Biskupiak J J Pain Palliat Care Pharmacother; 2008; 22(4):291-9. PubMed ID: 21923313 [TBL] [Abstract][Full Text] [Related]
6. Dose intensity in the treatment of diffuse large-cell lymphoma. Anderson JR; Santarelli MT; Peterson B J Clin Oncol; 1990 Nov; 8(11):1927-8. PubMed ID: 2230883 [No Abstract] [Full Text] [Related]
7. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes. Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S J BUON; 2015; 20(3):820-8. PubMed ID: 26214636 [TBL] [Abstract][Full Text] [Related]
8. DNA repair in diffuse large B-cell lymphoma: a molecular portrait. Bret C; Klein B; Cartron G; Schved JF; Constantinou A; Pasero P; Moreaux J Br J Haematol; 2015 Apr; 169(2):296-9. PubMed ID: 25369781 [No Abstract] [Full Text] [Related]
9. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. Lossos IS; Czerwinski DK; Alizadeh AA; Wechser MA; Tibshirani R; Botstein D; Levy R N Engl J Med; 2004 Apr; 350(18):1828-37. PubMed ID: 15115829 [TBL] [Abstract][Full Text] [Related]
10. The clinician's decision of whether CHOP chemotherapy should be standard therapy for treatment of patients with diffuse histiocytic lymphoma. Connors JM Important Adv Oncol; 1990; ():227-33. PubMed ID: 2182521 [No Abstract] [Full Text] [Related]
11. [Markov models in clinical medicine]. Chouaid C Rev Mal Respir; 2004 Nov; 21(5 Pt 1):1007-9. PubMed ID: 15622351 [No Abstract] [Full Text] [Related]
12. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234 [TBL] [Abstract][Full Text] [Related]
13. Molecular outcome prediction in diffuse large-B-cell lymphoma. Alizadeh AA; Gentles AJ; Lossos IS; Levy R N Engl J Med; 2009 Jun; 360(26):2794-5. PubMed ID: 19553658 [No Abstract] [Full Text] [Related]
14. Therapy of diffuse large B-cell lymphomas. Pfreundschuh M Eur J Cancer; 2009 Sep; 45 Suppl 1():386-7. PubMed ID: 19775641 [No Abstract] [Full Text] [Related]
15. Mathematical modeling or waiting decades for an empirical answer? Djulbegovic B; Woodcock TM Med Decis Making; 1992; 12(1):77. PubMed ID: 1538636 [No Abstract] [Full Text] [Related]
16. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission. Huntington SF; Svoboda J; Doshi JA J Clin Oncol; 2015 May; 33(13):1467-74. PubMed ID: 25823735 [TBL] [Abstract][Full Text] [Related]
17. Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era. Yang DH; Ahn JS; Byun BH; Min JJ; Kweon SS; Chae YS; Sohn SK; Lee SW; Kim HW; Jung SH; Kim YK; Kim HJ; Bom HS; Lee JJ Ann Hematol; 2013 Apr; 92(4):471-9. PubMed ID: 23238895 [TBL] [Abstract][Full Text] [Related]
19. Salvage radiotherapy increases survival in people with residual disease after chemotherapy for advance diffuse large cell lymphoma. Kumar A; Soares HP Cancer Treat Rev; 2006 Oct; 32(6):487-90. PubMed ID: 16725265 [No Abstract] [Full Text] [Related]